Abstract
In the present study, we analysed 34 de novo diffuse large B cell lymphoma (DLCL) from a population-based lymphoma registry for alterations of the RB1 pathway at the genetic (RB1 and CDK4) and protein (pRb, cyclin D1, cyclin D3, CDK4, and E2F-1) level. The results were correlated with the data from our previous studies of CDKN2A deletion and hypermethylation, other p53 pathway components, p27Kip1 expression, and proliferation, as well as with clinical outcome, including prognosis. We found aberrant pRb expression in four (12%) of 34 DLCLs. One of these had a point mutation in intron 3 10 bp downstream of exon 3 generating a novel splice signal. Seven tumours (21%) showed cyclin D3 overexpression, including all three thyroid lymphomas (P = 0.006). Cyclin D3 overexpression and p16INK4A/pRb aberrations were mutually exclusive, supporting an oncogenic role for cyclin D3 in DLCL. p16INK4A inactivation, cyclin D3 overexpression, or aberrant pRb expression was identified in 18 of 34 DLCLs (53%). Combining these results with our previous p53 pathway studies showed that 82% of the de novoDLCLs had alterations of these pathways, and that both pathways were altered in 13 cases (38%). Low E2F-1 expression was associated with treatment failure (P = 0.020), and multivariate analysis of overall survival identified both low E2F-1 expression (relative risk = 6.9; P = 0.0037) and p16INK4Ainactivation (relative risk = 3.3; P = 0.0247) as independent prognostic markers. These data support a role of E2F-1 as tumour suppressor gene in lymphoma and strongly suggest that the RB1 and p53 pathways are important in the development of de novo DLCL. Furthermore, low E2F-1 expression and p16INK4A inactivation may serve as prognostic markers for patients with this type of lymphoma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others
References
Sherr CJ . Cancer cell cycles Science 1996 274: 1672–1677
Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR . The E2F transcription factor is a cellular target for the RB protein Cell 1991 65: 1053–1061
Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J-Y, Livingston DM . Functional interactions of the retinoblastoma protein with mammalian D-type cyclins Cell 1993 73: 487–497
Serrano M, Hannon GJ, Beach D . A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 Nature 1993 366: 704–707
Polyak K, Kato J-Y, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A . p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest Genes Dev 1994 8: 9–22
Otterson GA, Kratzke RA, Coxon A, Kim YW, Kaye FJ . Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB Oncogene 1994 9: 3375–3378
Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN . CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated Cancer Res 1996 56: 150–153
He J, Allen JR, Collins VP, Allalunis-Turner MJ, Godbout R, Day RS III, James CD . CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines Cancer Res 1994 54: 5804–5807
Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL, Vousden KH . p14ARF links the tumour suppressors RB and p53 Nature 1998 395: 124–125
Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA . The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53 Cell 1998 92: 713–723
Wingo PA, Ries LAG, Giovino GA, Miller DS, Rosenberg HM, Shopland DR, Thun MJ, Edwards BK . Annual report to the nation on the status of cancer, 1973–1996, with a special section on lung cancer and tobacco smoking J Natl Cancer Inst 1999 91: 675–690
Chan WC, Armitage JO, Gascoyne R, Connors J, Close P, Jacobs P, Norton A, Lister TA, Pedrinis E, Cavalli F, Berger F, Coiffier B, Ho F, Liang R, Schauer A, Hiddemann W, Diebold J, MacLennan KA, Müller-Hermelink HK, Nathwani BN, Weisenburger DD, Harris NL, Anderson JR, Roy P . A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma Blood 1997 89: 3909–3918
Ries LAG, Kosary CL, Hankey BF, Miller BA, Edwards BK . SEER Cancer Statistics Review, 1973–1996 National Cancer Institute: Bethesda 1999
Offit K, Chaganti RSK . Chromosomal aberrations in non-Hodgkin's lymphoma. Biologic and clinical correlations Hematol Oncol Clin North Am 1991 5: 853–869
Ye BH, Lista F, Lo Coco F, Knowles DM, Offit K, Chaganti RSK, Dalla-Favera R . Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma Science 1993 262: 747–750
Møller MB, Ino Y, Gerdes A-M, Skjødt K, Louis DN, Pedersen NT . Aberrations of the p53 pathway components p53, MDM2, and CDKN2A appear independent in diffuse large B cell lymphoma Leukemia 1999 13: 453–459
Møller MB, Skjødt K, Mortensen LS, Pedersen NT . Clinical significance of cyclin-dependent kinase inhibitor p27Kip1 expression and proliferation in non-Hodgkin's lymphoma: independent prognostic value of p27Kip1 Br J Haematol 1999 105: 730–736
Møller MB, Gerdes A-M, Skjødt K, Mortensen LS, Pedersen NT . Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin's lymphoma Clin Cancer Res 1999 5: 1085–1091
Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Müller-Hermelink HK, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA . A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group Blood 1994 84: 1361–1392
Møller MB, d'Amore F, Christensen BE . Testicular lymphoma: a population-based study of incidence, clinicopathological correlations and prognosis Eur J Cancer 1994 30A: 1760–1764
Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G, Cabanillas F, Canellos GP, Coiffier B, Connors JM, Cowan RA, Crowther D, Dahlberg S, Engelhard M, Fisher RI, Gisselbrecht C, Horning SJ, Lepage E, Lister TA, Meerwald JH, Montserrat E, Nissen NI, Oken MM, Peterson BA, Tondini C, Velasquez WA, Yeap BY . A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project New Engl J Med 1993 329: 987–994
Zukerberg LR, Benedict WF, Arnold A, Dyson N, Harlow E, Harris NL . Expression of the retinoblastoma protein in low-grade B-cell lymphoma: relationship to cyclin D1 Blood 1996 88: 268–276
Doglioni C, Chiarelli C, Macri E, Dei Tos AP, Meggiolaro E, Dalla Palma P, Barbareschi M . Cyclin D3 expression in normal, reactive and neoplastic tissues J Pathol 1998 185: 159–166
Lai R, Medeiros LJ, Coupland R, McCourty A, Brynes RK . Immunohistochemical detection of E2F-1 in non-Hodgkin's lymphomas: a survey of 124 cases Mod Pathol 1998 11: 457–463
Naitoh H, Shibata J, Kawaguchi A, Kodama M, Hattori T . Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer Am J Pathol 1995 146: 1161–1169
Cordon-Cardo C, Wartinger D, Petrylak D, Dalbagni G, Fair WR, Fuks Z, Reuter VE . Altered expression of the retinoblastoma gene produkt: prognostic indicator in bladder cancer J Natl Cancer Inst 1992 84: 1251–1256
Grierson AJ, Hodgkins MA, Hancock BW, Goepel JR, Royds J, Goyns MH . Investigation of the RB-1 tumour suppressor gene in a United Kingdom series of non-Hodgkin's lymphomas Leuk Lymphoma 1996 23: 353–363
Aguilera NSI, Bijwaard KE, Duncan B, Krafft AE, Chu WS, Abbondanzo SL, Lichy JH, Taubenberger JK . Differential expression of cyclin D1 in mantle cell lymphoma and other non-Hodgkin's lymphomas Am J Pathol 1998 153: 1969–1976
Yandell DW, Dryja TP . Detection of sequence polymorphisms by enzymatic amplification and direct genomic sequencing Am J Hum Genet 1989 45: 547–555
Liu Y, Rasool O, Grandér D, Lindblom A, Einhorn S . Sequence variability of a prolonged tetranucleotide repeat Hum Mol Genet 1995 4: 727–729
Peltomäki P, Aaltonen LA, Sistonen P, Pylkkänen L, Mecklin JP, Jävinen H, Green JS, Jass JR, Weber JL, Leach FS, Pedersen GM, Hamilton SR, de la Chapelle A, Vogelstein B . Genetic mapping of a locus predisposing to human colorectal cancer Science 1993 260: 810–812
Cawkwell L, Bell SM, Lewis FA, Dixon MF, Taylor GR, Quirke P . Rapid detection of allele loss in colorectal tumours using microsatellites and fluorescent DNA technology Br J Cancer 1993 67: 1262–1267
Shimizu T, Toguchida J, Kato MV, Kaneko A, Ishizaki K, Sasaki MS . Detection of mutations of the RB1 gene in retinoblastoma patients by using exon-by-exon PCR-SSCP analysis Am J Hum Genet 1994 54: 793–800
Hogg A, Onadim Z, Baird PN, Cowell JK . Detection of heterozygous mutations in the RB1 gene in retinoblastoma patients using single-strand confirmation polymorphism analysis and polymerase chain reaction sequencing Oncogene 1992 7: 1445–1451
Lohmann DR, Brandt B, Höpping W, Parsarge E, Horsthemke B . Distinct RB1 gene mutations with low penetrance in hereditary retinoblastoma Hum Genet 1994 94: 349–354
Toguchida J, McGee TL, Paterson JC, Eagle JR, Tucker S, Yandell DW, Dryja TP . Complete genomic sequence of the human retinoblastoma susceptibility gene Genomics 1993 17: 535–543
Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA, Tubiana M . Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds Meeting J Clin Oncol 1989 7: 1630–1636
Martinez JC, Piris MA, Sanchez-Beato M, Villuendas R, Orradre JL, Algara P, Sanchez-Verde L, Martinez P . Retinoblastoma (Rb) gene product expression in lymphomas. Correlation with Ki67 growth fraction J Pathol 1993 169: 405–412
Nguyen PL, Zukerberg LR, Benedict WF, Harris NL . Immunohistochemical detection of p53, bcl-2, and retinoblastoma proteins in follicular lymphoma Am J Clin Pathol 1996 105: 538–543
Barrans SL, Haynes A, Fegan C, Jack AS, Morgan GJ . Immunohistochemical analysis of cell proliferation and oncogene expression in nodal diffuse large B-cell lymphoma Br J Haematol 1997 97: 31 (Abstr.)
Geradts J, Andriko JW, Abbondanzo SL . Loss of tumor suppressor gene expression in high-grade but not low-grade non-Hodgkin's lymphomas Am J Clin Pathol 1998 109: 669–674
Ballerini P, Gaidano G, Gong JZ, Tassi V, Saglio G, Knowles DM, Dalla-Favera R . Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma Blood 1993 81: 166–176
Krawczak M, Reiss J, Cooper DN . The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences Hum Genet 1992 90: 41–54
Koeberl DD, Bottema CDK, Ketterling RP, Bridge PJ, Lillicrap DP, Sommer SS . Mutations causing hemophilia B: direct estimate of the underlying rates of spontaneous germ-line transitions, transversions, and deletions in a human gene Am J Hum Genet 1990 47: 202–217
Weide R, Tiemann M, Pflüger K-H, Köppler H, Parvizl B, Wacker H-H, Kreipe HH, Havemann K, Parwaresch MR . Altered expression of the retinoblastoma gene product in human high grade non-Hodgkin's lymphomas Leukemia 1994 8: 97–101
Hayashi K, Yandell DW . How sensitive is PCR-SSCP? Hum Mutat 1993 2: 338–346
Ohtani-Fujita N, Fujita T, Aoike A, Osifchin NE, Robbins PD, Sakai T . CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene Oncogene 1993 8: 1063–1067
Bartkova J, Lukas J, Strauss M, Bartek J . Cyclin D3: requirement for G1/S transition and high abundance in quiescent tissues suggest a dual role in proliferation and differentiation Oncogene 1998 17: 1027–1037
Petrucci MT, Ariola C, Ricciardi MR, Pisegna S, Fimia GM, Annino L, Testi AM, Lo Coco F, Mandelli F, Tafuri A . Molecular control of cell cycle in normal and neoplastic hemopoiesis: p16, CDK4, and Rb showed a common tumorigenesis pattern in acute lymphoblastic leukemia Blood 1996 88: 120b (Abstr.)
Ando K, Griffin JD . Cdk4 integrates growth stimulatory and inhibitory signals during G1 phase of hematopoietic cells Oncogene 1995 10: 751–755
Dreyling MH, Bullinger L, Ott G, Stilgenbauer S, Müller-Hermelink HK, Bentz M, Hiddemann W, Döhner H . Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma Cancer Res 1997 57: 4608–4614
Haas K, Staller P, Geisen C, Bartek J, Eilers M, Möröy T . Mutual requirement of CDK4 and Myc in malignant transformation: evidence for cyclin D1/CDK4 and p16INK4A as upstream regulators of Myc Oncogene 1997 15: 179–192
Li Y, Nichols MA, Shay JW, Xiong Y . Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb Cancer Res 1994 54: 6078–6082
Pierce AM, Gimenez-Conti IB, Schneider-Broussard R, Martinez LA, Conti CJ, Johnson DG . Increased E2F1 activity induces skin tumors in mice heterozygous and nullizygous for p53 Proc Natl Acad Sci USA 1998 95: 8858–8863
Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E, Dyson NJ . Tumor induction and tissue atrophy in mice lacking E2F-1 Cell 1996 85: 537–548
Field SJ, Tsai FY, Kuo F, Zubiaga AM, Kaelin WG Jr, Livingston DM, Orkin SH, Greenberg ME . E2F-1 functions in mice to promote apoptosis and suppress proliferation Cell 1996 85: 549–561
Banerjee D, Schnieders B, Fu JZ, Adhikari D, Zhao SC, Bertino JR . Role of E2F-1 in chemosensitivity Cancer Res 1998 58: 4292–4296
Volm M, Koomägi R, Rittgen W . Clinical implications of cyclins, cyclin-dependent kinases, RB and E2F1 in squamous-cell lung carcinoma Int J Cancer 1998 79: 294–299
Rabbani F, Richon VM, Orlow I, Lu ML, Drobnjak M, Dudas M, Charytonowicz E, Dalbagni G, Cordon-Cardo C . Prognostic significance of transcription factor E2F-1 in bladder cancer: genotypic and phenotypic characterization J Natl Cancer Inst 1999 91: 874–881
Garcia-Sanz R, Gonzalez M, Vargas M, Chillon MC, Balanzategui A, Barbon M, Flores MT, San Miguel JF . Deletions and rearrangements of cyclin-dependent kinase 4 inhibitor gene p16 are associated with poor prognosis in B cell non-Hodgkin's lymphomas Leukemia 1997 11: 1915–1920
Grønbøk K, de Nully Brown P, Ralfkiaer E, Zeuthen J, Guldberg P . Concurrent disruption of the p16-pRb and ARF-p53 pathways predicts poor prognosis in non-Hodgkin's lymphoma Proc Am Assn Cancer Res 1999 40: 282 (Abstr.)
Acknowledgements
We thank Jan Alsner for kindly providing DNA from retinoblastoma patients with known RB1 mutations. We also appreciate the excellent technical assistance of Marianne Christensen, Maj-Britt S Berg, Lene Nielsen and Bodil Harder. The work was supported in part by the Danish Medical Research Council Grant 9400660.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Møller, M., Kania, P., Ino, Y. et al. Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A. Leukemia 14, 898–904 (2000). https://doi.org/10.1038/sj.leu.2401761
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401761